Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pacira Pharmaceuticals buy Barclays PLC

Start price
€26.80
08.05.24 / 50%
Target price
€35.35
08.05.25
Performance (%)
-25.75%
End price
€19.90
09.05.25
Summary
This prediction ended on 09.05.25 with a price of €19.90. The price of Pacira Pharmaceuticals has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.75%. Barclays_PLC has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Pacira Pharmaceuticals 4.902% 4.902% 15.676%
iShares Core DAX® 0.734% 1.458% 17.980%
iShares Nasdaq 100 -2.686% -0.146% 3.810%
iShares Nikkei 225® -2.261% -2.729% 11.679%
iShares S&P 500 -1.346% 0.467% 1.970%

Comments by Barclays_PLC for this prediction

In the thread Pacira Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) -25.75%
Target price 35.351
Change
Ends at 08.05.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat

In the thread Trading Pacira Pharmaceuticals
Prediction Buy
Perf. (%) -25.75%
Target price 35.351
Change
Ends at 08.05.25

Die von Barclays_PLC gewählte maximale Laufzeit wurde überschritten

Stopped prediction by Barclays_PLC for Pacira Pharmaceuticals

buy
Pacira Pharmaceuticals

Start price
Target price
Perf. (%)
€26.20
23.10.23
€53.51
23.10.24
-38.93%
24.10.24